Mayo Clinic January 14, 2025
John Halamka

Mayo Clinic’s Tapestry Study has demonstrated that next generation genetic analysis can have a significant impact on patient care.

By John Halamka, M.D., President, Mayo Clinic Platform and Paul Cerrato, MA, senior research analyst and communications specialist, Mayo Clinic Platform

On April 14, 2003, the world learned that the Human Genome Project had been completed. As the National Institutes of Health pointed out, it was one of the greatest scientific accomplishments in history and the first completed sequence of the human genome, the DNA that determines not only the color of our eyes, but our susceptibility to many diseases. Unfortunately, many clinicians were disappointed when they realized the data didn’t have an immediate effect on routine patient care. Why...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Clinical Trials, Health System / Hospital, Pharma / Biotech, Precision Medicine, Provider, Trends
23andMe is potentially selling more than just genetic data. Survey info is just as much a privacy problem
AIDAVA is harnessing data altruism to advance personalised medicine
The Download: generative AI therapy, and the future of 23andMe’s genetic data
23andMe: How to delete your genetic data
FTC: Customer details must remain private 23andMe bankruptcy

Share This Article